Late-Breaking Clinical Trials III: Interventional Cardiology
Monday, April 4, 10:45-AM 12:15 PM
The aim of ISAR-CABG trial is to compare the efficacy of drug-eluting and bare metal stents (DES and BMS) to reduce reblockage of bypass grafts after coronary stenting. Several different DES are being compared to BMS.
Studies have shown that DES significantly reduce in-stent restenosis and the subsequent need for target vessel revascularization compared with BMS. But this phenomenon has not been thoroughly studied in coronary artery bypass graft lesions. The ISAR-CABG trial will provide some answers regarding this patient population.
The RIVAL trial is comparing the transradial PCI access strategy and the transfemoral PCI access strategy in acute coronary syndrome patients with unstable angina, non-STEMI or STEMI patients who planned to be treated PCI.
RIVAL intends to recruit 7,000 patients and is the largest study comparing the two arterial access approaches. "The challenge, even with 7,000 patients, is that we may not be able to show a difference in survival, because patients in general tend to do well after angioplasty, in terms of living longer," says Sunil V. Rao, MD, director of the cardiac cath lab at Durham VA Medical Center, Durham, N.C.
The RESOLUTE US Study is evaluating the safety and efficacy of the Endeavor Resolute zotarolimus-eluting stent (Medtronic) for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter of 2.25 mm to 4.2 mm.
Compared to the phosphorylcholine polymer used in Medtronic's Endeavor stent, the Resolute uses a proprietary BioLinx polymer that is designed to extend the duration of drug exposure in the vessel. In this session, investigators will report the one-year outcomes.
The PLATINUM Trial is evaluating the safety and effectiveness Boston Scientific's Promus Element everolimus-eluting stent for the treatment of patients with up to two de novo coronary artery lesions. According to the company, the Promus stents utilize a platinum chromium alloy, which helps them maintain high radial strength and allow for good visualization.
This session is a must attend for interventional cardiologists who want to get a better sense of the potential changes around the bend for treating coronary lesions.
Speaker Information
The aim of ISAR-CABG trial is to compare the efficacy of drug-eluting and bare metal stents (DES and BMS) to reduce reblockage of bypass grafts after coronary stenting. Several different DES are being compared to BMS.
Studies have shown that DES significantly reduce in-stent restenosis and the subsequent need for target vessel revascularization compared with BMS. But this phenomenon has not been thoroughly studied in coronary artery bypass graft lesions. The ISAR-CABG trial will provide some answers regarding this patient population.
The RIVAL trial is comparing the transradial PCI access strategy and the transfemoral PCI access strategy in acute coronary syndrome patients with unstable angina, non-STEMI or STEMI patients who planned to be treated PCI.
RIVAL intends to recruit 7,000 patients and is the largest study comparing the two arterial access approaches. "The challenge, even with 7,000 patients, is that we may not be able to show a difference in survival, because patients in general tend to do well after angioplasty, in terms of living longer," says Sunil V. Rao, MD, director of the cardiac cath lab at Durham VA Medical Center, Durham, N.C.
The RESOLUTE US Study is evaluating the safety and efficacy of the Endeavor Resolute zotarolimus-eluting stent (Medtronic) for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter of 2.25 mm to 4.2 mm.
Compared to the phosphorylcholine polymer used in Medtronic's Endeavor stent, the Resolute uses a proprietary BioLinx polymer that is designed to extend the duration of drug exposure in the vessel. In this session, investigators will report the one-year outcomes.
The PLATINUM Trial is evaluating the safety and effectiveness Boston Scientific's Promus Element everolimus-eluting stent for the treatment of patients with up to two de novo coronary artery lesions. According to the company, the Promus stents utilize a platinum chromium alloy, which helps them maintain high radial strength and allow for good visualization.
This session is a must attend for interventional cardiologists who want to get a better sense of the potential changes around the bend for treating coronary lesions.
Speaker Information
- Julinda Mehilli, MD, et al, Deutsches Herzzentrum, Munich, Germany -- Long-Term Outcomes after Use of Drug-Eluting Stents and Bare Metal Stents for the Treatment of Saphenous Vein Graft Lesions: Results of the Randomized ISAR-CABG Trial
- Sanjit S. Jolly, MD, et al, Hamilton Health Sciences, Hamilton, Canada -- Rival Trial: A Randomized Comparison of Radial versus Femoral Access for Coronary Angiography or Intervention in Patients with Acute Coronary Syndromes
- Martin B. Leon, MD, et al, Columbia University Medical Center, New York City -- One Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study —
- Gregg W. Stone, MD, et al, Columbia University Medical Center, New York City -- A Prospective, Randomized, Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent: The PLATINUM Trial
- Carlo Briguori, MD, et al, Clinica Mediterranea, Naples, Italy -- Renal Insufficiency Following Contrast Media Administration Trial Ii (REMEDIAL II): Renalguard System In High-risk Patients For Contrast-induced Acute Kidney Injury